Reference
Lee SB, et al. Real-World Effectiveness and Safety of Adalimumab in Korean Patients with Intestinal Behcet's Disease: 52-Week Results from a KASID Multicenter Study. Gut and Liver 16 (Suppl. 6): 139 abstr. EP03-047, Dec 2022. Available from: URL: https://www.gutnliver.org/journal/view.html?pn=vol&uid=2134&vmd=Full [abstract]
Rights and permissions
About this article
Cite this article
Adalimumab. Reactions Weekly 1996, 17 (2024). https://doi.org/10.1007/s40278-024-53470-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-024-53470-2